The Effect of Education Given to Hemodialysis Patients With Pecha Kuka Method on Attitude Towards Diet Therapy and Compliance With Fluid Restriction

February 21, 2026 updated by: Gülcan Bahçecioğlu Turan, Ataturk University

Hemodialysis complex treatment regimen includes fluid and diet management. In this context, it is recommended that patients choose foods with low sodium, potassium and phosphorus content, maintain adequate protein intake, and regulate their daily fluid intake not exceeding 1-2 liters. In maintaining the health of hemodialysis patients; It is very important that they comply with the treatment program, diet and fluid restrictions. As the life expectancy increases, the time spent with chronic disease also increases, and both the patient himself and his relatives living in the same house are faced with this chronic disease and accompanying stress factors for a longer period of time, making it difficult for them to adapt to the progression of the disease.

Pecha Kucha (PK), meaning "chat voice" or "chat" in Japanese, refers to a well-crafted, fast and concise presentation format. In a PK presentation, each presenter is only allowed to show 20 PowerPoint slides for 20 seconds each on a timer. When the literature was examined, no study was found that evaluated the effect of the education given to hemodialysis patients with the Pecha Kuka method on the attitude towards diet therapy and compliance with fluid restriction. In addition, it is thought that this short and concise education method will contribute to a better understanding of the attitudes of patients receiving hemodialysis treatment towards diet therapy and their compliance with fluid restriction, thus providing important data for future studies.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Diet is one of the most important elements of HD treatment. Kidney disease can be slowed down with diet. There are important issues in the diet of individuals receiving HD treatment. Adequate energy consumption comes first. Individuals receiving HD treatment must meet the energy requirements needed to maintain their health, as well as perform their metabolic functions. Adequate protein intake is one of the important issues in the diet in patients receiving HD treatment. Compliance with disease treatment; it is briefly defined as "individual compliance with medical treatment and health recommendations". During the period of hemodialysis treatment, one of the areas where individuals have difficulty in adapting is diet and fluid restriction. Because the disease and HD treatment directly affect the eating habits and preferences of individuals. As with all chronic diseases, it is very important for individuals who continue HD treatment to comply with the drug treatment program, diet and fluid restrictions in order to maintain their health. refers to a fast and concise presentation format. It was created in 2003 by architects Astrid Klein and Mark Dytham, who hoped to give young designers the opportunity to present their work in a short, fast-paced setting. In a PK presentation, each presenter is only allowed to show 20 PowerPoint slides for 20 seconds each on a timer. In other words, the presenter has only 20 seconds to discuss each slide before the next slide appears, and the presentation time is limited to 6 minutes and 40 seconds. Ideas are explained visually with pictures and graphics, and there is little text on the slides.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: kübra toraman, STD

Study Locations

  • Turkey (Türkiye)
    • Merkez
      • Elâzığ, Merkez, Turkey (Türkiye), 23000
        • Gülcan B Turan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • The patient does not have any impairment (such as vision, speech and hearing) that prevents him from communicating.
  • Accepting the research
  • Being receiving hemodialysis treatment
  • Ability to communicate adequately
  • Absence of psychiatric problems

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: control
Routine maintenance will be applied.
Experimental: Experimental:
pecha kucha will be practiced
Behavioral: pecha kucha
pecha kucha training

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Attitude Scale Towards Dietary Treatment of Hemodialysis Patients
Time Frame: 1 hours later

"Attitude Scale Towards Dietary Treatment of Hemodialysis Patients" is a 16-item scale developed by Onbe and Kanda in 2018 to determine the attitudes of patients towards diet therapy. It is a 4 likert scale.

Each item represents 1-Strongly agree, 2-Agree, 3-Disagree, 4-Strongly Disagree. This scale consists of 3 sub-dimensions.

  1. Sub size; "Behavioral tendency affected by cognition" includes 7 items (1,2,3,4,5,6,7).
  2. Sub-dimension; "Behavioral tendency affected by food culture" includes 6 (8,9,10,11,12,13) items.
  3. Sub-dimension; "Negative effect that changes diet" includes 3 items (14,15,16). The last three items in the scale are reversed.

Higher scores obtained from the scale indicate that attitudes are better. Effect on Retention and Fluid Restriction Compliance
1 hours later
Dialysis Diet and Fluid Restriction Compliance Scale
Time Frame: 1 hours later
It was developed by Vlaminck et al. (2001), and its Turkish validity and reliability study was performed by Kara (2009) in hemodialysis patients. WHO is a four-item self-report tool used to evaluate non-adherence to diet and fluid intake restriction in hemodialysis patients. Two items in the scale deal with diet (items 1 and 2), and the other two deal with fluid restriction (items 3 and 4) in terms of frequency and degree. The frequency of non-compliance with diet and fluid restriction is based on the behaviors of the patients in the previous 14 days. The degree of non-compliance with diet and fluid restriction has a Likert-type structure scored between 0-4 (No non-compliance = 0, Mild = 1, Moderate = 2, Severe = 3, Very severe =4) The Cronbach alpha coefficient of the scale was reported as 0.70.
1 hours later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ataturk University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 12, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 10, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 22, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 24, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2023/ 04- 12

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings